Analyte-driven self-assembly of graphene oxide sheets onto hydroxycamptothecin-functionalized upconversion nanoparticles for the determination of type I topoisomerases in cell extracts

Exploring the use of upconversion nanoparticles in chemical and biological sensors: from surface modifications to point-of-care devices

Upconversion nanoparticles (UCNPs) have emerged as promising luminescent nanomaterials due to their unique features that allow the overcoming of several problems associated with conventional fluorescent probes. Although UCNPs have been used in a broad range of applications, it is probably in the field of sensing where they best evidence their potential. UCNP-based sensors have been designed with high sensitivity and selectivity, for detection and quantification of multiple analytes ranging from metal ions to biomolecules. In this review, we deeply explore the use of UCNPs in sensing systems emphasizing the most relevant and recent studies on the topic and explaining how these platforms are constructed. Before diving into UCNP-based sensing platforms it is important to understand the unique characteristics of these nanoparticles, why they are attracting so much attention, and the most significant interactions occurring between UCNPs and additional probes. These points are covered over the first two sections of the article and then we explore the types of fluorescent responses, the possible analytes, and the UCNPs' integration with various material types such as gold nanostructures, quantum dots and dyes. All the topics are supported by analysis of recently reported sensors, focusing on how they are built, the materials' interactions, the involved synthesis and functionalization mechanisms, and the conjugation strategies. Finally, we explore the use of UCNPs in paper-based sensors and how these platforms are paving the way for the development of new point-of-care devices.

A patent review of topoisomerase I inhibitors (2016-present)

INTRODUCTION

Topoisomerases are important targets for therapeutic improvement in the treatment of some diseases, including cancer. Inhibitors and poisons of topoisomerase I can limit the activity of this enzyme in its enzymatic cycle. This fact implies an anticancer effect of these drugs, since most cancer cells are characterized by both a higher activity of topoisomerase I and a higher replication rate compared to non-cancerous cells. Clinically approved inhibitors include camptothecin (CPT) and its derivatives. However, their limitations have encouraged different research groups to prepare new compounds, proof of which are the numerous research works and patents, some of them in the last five years.

AREAS COVERED

This review covers patent literature on topoisomerase I inhibitors and their application published between 2016-present.

EXPERT OPINION

The highest contribution toward patent development has been obtained from academics or small biotechnology companies. The most important fields of innovation include the preparation of prodrugs or inhibitors combined with other agents, as biocompatible polymers or antibodies. A promising development of topoisomerase I inhibitors is expected in the next years, directed to the treatment of diverse diseases, specifically toward different types of cancer and infectious diseases, among others.

Sensors/nanosensors based on upconversion materials for the determination of pharmaceuticals and biomolecules: An overview

Upconversion materials have been the focus of a large body of research in analytical and clinical fields in the last two decades owing to their ability to convert light between various spectral regions and their particular photophysical features. They emit efficient and sharp ultraviolet (UV) or visible luminescence after excitation with near-infrared (NIR) light. These features overcome some of the disadvantages reported for conventional fluorescent materials and provide opportunities for high sensitivity chemo-and bio-sensing. Here, we review studies that used upconversion materials as sensors for the determination of pharmaceuticals and biomolecules in the last two decades. The articles included in this review were retrieved from the SCOPUS database using the search phrases: "upconversion nanoparticles for determination of pharmaceutical compounds", and "upconversion nanoparticles for determination of biomolecules". Details of each developed upconversion nanoparticles based sensor along with their relevant analytical parameters are reported and carefully explained.

Affinity binding-mediated fluorometric protein assay based on the use of target-triggered DNA assembling probes and aptamers labelled with upconversion nanoparticles: application to the determination of platelet derived growth factor-BB

The target-triggered DNA assembling probe is presented for highly selective protein detection. Target-triggered DNA assembling is used in an amplification strategy based on affinity binding for identification and determination of proteins in general. Specifically, it was applied to the platelet derived growth factor-BB (PDGF-BB). A hairpin DNA (H-DNA) probe was designed containing (a) an aptamer domain for protein recognition and (b) a blocked DNAzyme domain for DNAzyme cleavage. An assistant DNA (A-DNA) probe containing aptamer and complementary domains was also employed to recognize protein and to induce DNA assembly. Once H-DNA and A-DNA recognize the same protein, H-DNA and A-DNA are in close proximity to each other. This induces DNA assembling for protein-triggered complex (Protein-Complex) with free DNAzyme domains. The free DNAzymes trigger the circular cleavage of molecular beacons for amplified signals. The assay is performed by fluorometry at an excitation wavelength of 980 nm and by collecting fluorescence at 545 nm. The platelet derived growth factor-BB (PDGF-BB) was accurately identified and selectively determined by this assay with a 22 pM detection limit (using the 3σ criterion). The responses for PDGF-BB is nearly 6-fold higher than for PDGF-AB, and 16-fold higher than PDGF-AA. This upconversion assay avoids any interference by the autofluorescence of biological fluids. Graphical abstractSchematic representation of the principle of the target-triggered DNA assembling probes mediated amplification strategy based on affinity binding for PDGF-BB. The UCNP probe is used for the quantitation of PDGF-BB with high selectivity.

Formulation of injectable glycyrrhizic acid-hydroxycamptothecin micelles as new generation of DNA topoisomerase I inhibitor for enhanced antitumor activity

To develop a new drug delivery system is one of the useful approaches to break through the limitation of hydroxycamptothecin (HCPT), a typical DNA topoisomerase I (Topo I) inhibitor in clinical appliance. Injectable glycyrrhizic acid-hydroxycamptothecin (GL-HCPT) micelles that were able to dramatically improve the solubility and stability of HCPT were prepared through self-assembly process and evaluated both in vitro and in vivo. With a mean particle size (PS) of 105.7 ± 9.7 nm and a drug loading (DL) of 9.0 ± 1.5%, GL-HCPT micelles were rapidly internalized by HepG2 cells after 1 h, significantly increasing the intracellular accumulation of HCPT. Compared with the current used HCPT injection and HCPT/GL physical mixture, GL-HCPT micelles showed enhanced antitumor activity against liver cancer cells (HepG2 and Huh7) as well as a superior suppression on the tumor growth of HepG2 tumor bearing mice. Interestingly, GL-HCPT micelles gathered in liver and simultaneously reduced the drug accumulation in normal tissues, thereby exhibiting minimal cytotoxicity to human normal liver cells (LO2). Therefore, we offered a convenient and cost-effective strategy to construct an intravenous drug delivery system (GL-HCPT micelles) as new generation of DNA Topo I inhibitor for enhanced cancer chemotherapy.